Smith & Nephew (LON:SN) Stock Price Passes Above 200-Day Moving Average – Should You Sell?

Shares of Smith & Nephew plc (LON:SN) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,045.53 ($14.35) and traded as high as GBX 1,101.50 ($15.12). Smith & Nephew shares last traded at GBX 1,096.50 ($15.05), with a volume of 1,074,849 shares.

Smith & Nephew Trading Up 0.4%

The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The business’s fifty day simple moving average is GBX 1,064.34 and its two-hundred day simple moving average is GBX 1,045.53. The company has a market cap of £12.07 billion, a price-to-earnings ratio of 39.64, a PEG ratio of 0.46 and a beta of 0.62.

Insiders Place Their Bets

In other Smith & Nephew news, insider Jeremy (Jez) Maiden bought 1,855 shares of the stock in a transaction dated Thursday, May 1st. The shares were acquired at an average cost of GBX 1,070 ($14.68) per share, for a total transaction of £19,848.50 ($27,238.23). 0.19% of the stock is owned by corporate insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.